Introduction

Large scale data from thousands of cases are required to precisely evaluate medical treatments and compare outcomes among different modalities. In the field of thoracic malignancy, the tumor, node, and metastasis (TNM) staging system proposed by the Union for International Cancer Control (UICC) is based on analyses of global databases, while clinical studies using national or international databases are also now common. In Japan, several nationwide general thoracic surgery databases have been established. In the present study, the current status of nationwide databases of Japanese cases is reviewed.

Japanese associations that maintain nationwide databases of thoracic disease and their relationships

Several academic societies in Japan are focusing on thoracic diseases, including the development of nationwide databases...
executed by each society or in collaboration with several others. The features of these associations and databases are summarized in Table 1. Japanese Association of Thoracic Surgery (JATS) is the leading society for cardiovascular and general thoracic surgery in Japan and approximately 40% of its members are primarily involved in general thoracic surgery. The JACS is an organization of general thoracic surgeons and the representative society for lung, mediastinum, pleura, and diaphragm surgery. Most of their members also belong to JATS.

JATS maintains its own database, while JATS and JACS collaboratively administer the Japanese Board of General Thoracic Surgeons, which enables JATS to review all thoracic operations performed throughout Japan. JATS has conducted an academic survey to determine the numbers of surgical procedures and operative mortality since 1986 (1), which shows that the total number of general thoracic surgery cases in 1986 was 15,544 and steadily increased to reach 75,306 in 2013, a 4.8-fold increase during that 28-year period. The proportion of diseases treated in 2013 is shown in Figure 1.

The Japan Lung Cancer Society (JLCS), Japanese Respiratory Society (JRS), and Japan Society for Respiratory Endoscopy (JSRE) consist of clinicians of all specialties related to thoracic disease. JACS, JLCS, JRS, and JSRE established the Japanese Joint Committee of Lung Cancer Registry (JJCLCR), which manages the Japanese Lung Cancer Registry, a nationwide database. JJCLCR has conducted five nationwide database projects since 1994, most of which are retrospective collections of surgically treated cases, as shown in Table 2, with data from a total of 50,949 patients stored there. In addition, the JJCLCR database includes information showing detailed long-term

Table 1 Japanese thoracic disease associations and related databases

<table>
<thead>
<tr>
<th>Association</th>
<th>Database</th>
</tr>
</thead>
<tbody>
<tr>
<td>JATS</td>
<td>JATS database: procedure-based annual survey</td>
</tr>
<tr>
<td>JACS</td>
<td>Thymic epithelial tumor retrospective database developed in 1999</td>
</tr>
<tr>
<td>JLCS</td>
<td>JJCLCR database: oncology-based database: significant part of IASC staging committee database</td>
</tr>
<tr>
<td>JRS</td>
<td>JJCLCR database</td>
</tr>
<tr>
<td>JSRE</td>
<td>JJCLCR database</td>
</tr>
<tr>
<td>JART</td>
<td>Thymic epithelial tumor retrospective database developed in 2012</td>
</tr>
<tr>
<td>Japanese Association for Lung and Heart-Lung Transplantation</td>
<td>Lung transplantation prospective database</td>
</tr>
</tbody>
</table>


Figure 1 Proportion of medically treatable diseases treated by surgery in 2013.

Table 2 Database projects of JJCLCR

<table>
<thead>
<tr>
<th>Project</th>
<th>Subjects</th>
<th>Method</th>
<th>Number of cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>First</td>
<td>Surgical cases in 1989</td>
<td>Retrospective</td>
<td>3,643</td>
</tr>
<tr>
<td>Second</td>
<td>Surgical cases in 1994</td>
<td>Retrospective</td>
<td>7,408</td>
</tr>
<tr>
<td>Third</td>
<td>All cases in 2002</td>
<td>Prospective</td>
<td>14,925</td>
</tr>
<tr>
<td>Fourth</td>
<td>Surgical cases in 1999</td>
<td>Retrospective</td>
<td>13,310</td>
</tr>
<tr>
<td>Fifth</td>
<td>Surgical cases in 2004</td>
<td>Retrospective</td>
<td>11,663</td>
</tr>
<tr>
<td>Total</td>
<td>-</td>
<td>-</td>
<td>50,949</td>
</tr>
</tbody>
</table>

JJCLCR, Japanese Joint Committee of Lung Cancer Registry.
According to the JATS database, lung cancer surgery occupies 49.1% of surgical procedures and is the most common target of general thoracic surgery in Japan. The annual trend for number of patients receiving surgery for primary lung cancer is shown in Figure 2. The number of operations increased from 6,421 in 1986 to 37,008 in 2013, a 5.76-fold increase during those 28 years.

The most recent JATS survey of the characteristics of lung cancer surgery was conducted in 2013 (1) and age distribution shown by those findings is presented in Figure 3. The most prevalent age group was 70 to 79 years and patients at least 70 years old occupied 52.2% of the entire population. Pathological types are shown in Figure 4, with adenocarcinoma by far the most common histology occupying nearly 70%, followed by squamous cell carcinoma. Each of the other histological types encompasses less than 2% of all cases. Pathological stages are shown in Figure 5 and the operative procedures employed are noted in Figure 6. The 30-day mortality rates according to operative procedure are presented in Table 3.

Long-term outcomes of lung cancer surgery can be obtained by analysis of the JJCLCR database (2). Overall survival rates of lung cancer patients who underwent surgical treatment in 1989, 1994, 1999, and 2004 are shown in Figure 7. The 5-year overall survival rate of the entire patient population in 2004 was 69.6%, which improved from
Table 3 Postoperative 30-day mortality rates for lung cancer surgery procedures

<table>
<thead>
<tr>
<th>Procedure</th>
<th>30-day mortality (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pneumonectomy</td>
<td>3.6</td>
</tr>
<tr>
<td>Lobectomy</td>
<td>0.3</td>
</tr>
<tr>
<td>Sleeve lobectomy</td>
<td>1.1</td>
</tr>
<tr>
<td>Segmentectomy</td>
<td>0.4</td>
</tr>
<tr>
<td>Wedge resection</td>
<td>0.3</td>
</tr>
<tr>
<td>All patients</td>
<td>0.33</td>
</tr>
</tbody>
</table>

Figure 6 Operative procedures adopted in lung cancer patients treated in 2013.

Figure 7 Overall survival trends of lung cancer patients who received surgical treatment.

47.8% over the previous 15 years. Trends for pathological stage and tumor size are shown in Figures 8 and 9, respectively. The proportions of early stage disease and small tumors are growing, resulting in a recent increase in limited resection cases.

Overall survival rates in association with pathological stage in patients who underwent surgery in 2004 are shown in Figure 10. Also, the 5-year survival and rates of recurrence for each pathological stage are shown in Table 4. Tumor relapse was observed in 19.8% of all patients. The 5-year survival rate was as high as 86.8% in stage IA patients, though 12.3% of those experienced tumor recurrence. In patients with stage IIB or greater disease, the rate of relapse was more than 50%.

Figure 8 Trends of pathological stage of lung cancer patients surgically treated with resection.

Figure 9 Trends in tumor size in patients with lung cancer surgically treated with resection.

Figure 10 Survival curves of lung cancer patients who received surgical treatment in 2004.
Clinical study of lung cancer using nationwide databases

Clinical studies using JJCLCR databases are presently being performed. Based on results of analyses of 11,663 patients who underwent surgery in 2004, we reported outcomes of those with both clinical N2 and pathological N2 disease (4), the oncological significance of visceral pleural invasion (5), survival of patients with pathological T3 according to the invaded organ (6), survival of patients with pathological T4 according to the invaded organ (7), survival according to adenocarcinoma subtype (8), outcomes of patients younger than 50 years in comparison with older patients (9), outcome of surgical treatment for small cell lung cancer (10), the significance of intraoperative pleural lavage cytology findings (11), and outcome of surgical treatment in cases with pleural dissemination and malignant pleural effusion (12).

Databases of thymic epithelial tumors and clinical study

According to the JATS database, the entire number of mediastinal tumors surgically treated throughout Japan in 2013 was 4,780 (1) and the proportions of tumors in those cases is shown in Figure 11. Thymoma was most commonly encountered among surgically treated mediastinal tumors and the annual trend for number of thymic epithelial tumors is shown in Figure 12.

The JJCLCR databases were submitted to the staging committee of the International Association for Study of Lung Cancer (IASLC) and detailed data from 47,306 patients were utilized to propose version 8 of the UICC TNM classification in 2015 (3). Also, a project to build a retrospective database of patients surgically treated in 2010 is currently undergoing and the outcomes of surgical treatments in more recent cases will be revealed in 2017. In addition, a prospective database project of non-surgically treated patients in Japan is also being developed. Patients with a diagnosis of unresectable primary lung cancer were enrolled in 2012 and final outcomes are currently being analyzed. This project is expected to elucidate the effectiveness of novel molecular target therapies introduced since 2000.
A second database project was initiated by JART in 2012, which is a retrospective collection of thymic epithelial tumor cases surgically treated during the 20-year period between 1991 and 2010. This JART database has been submitted to the IASLC staging committee as part of the global project for proposal of TNM classification of thymic epithelial tumors (15-17).

Recently, several novel findings related to these rare tumors have been reported following analysis of the JART databases. The members of JART reported the prognostic significance of the number of pleural dissemination lesions in Masaoka stage IVA thymoma cases (18), implications of postoperative radiation therapy (PORT) for thymoma and thymic carcinoma in patients with Masaoka stage III disease (19), the significance of an extended thymectomy for Masaoka stage I thymoma as compared to a simple thymectomy (20), the outcomes of surgery for stage III thymoma and prognostic significance of chest wall invasion (21), outcomes of surgical treatment for recurrent tumors (22), outcomes of surgery for thymic carcinoma (23), and the characteristics of myasthenia gravis associated with a thymic epithelial tumor (24).

China and South Korea have also established new associations with specific focus on thymic tumors and started their own database projects. Databases generated in East Asian countries have greatly contributed to the proposal for TNM classification of thymic epithelial tumors (15).

**Lung transplantation in Japan**

The Japanese Association for Lung and Heart-Lung Transplantation has developed a prospective nationwide database of lung transplantation in Japan, which contains clinical data collected from 466 patients who received lung transplantation or heart-lung transplantation from 1998 to 2015. Of those, lung transplantations from brain-dead and living related donors were performed in 283 and 181 cases, respectively. The operative procedure in brain-dead donor lung transplantation was single lung transplantation in 150 and bilateral double lung transplantation in 133 patients. Furthermore, heart-lung transplantation was performed in two patients. The 5-year overall survival rate in brain-dead donor single lung transplantation cases was 70.2%, while that in brain-dead double lung transplantation was 75.1% and in living related donor lung transplantation was 71.7%.

**Concluding remarks**

Nationwide databases in Japan are contributing to elucidation of trends and current status of general thoracic surgery cases. Detailed information obtained from a large-scale database is helpful for evaluation of treatment strategies, especially in cases of rare disease. In addition, international collaborative studies can be promoted by development of global database projects. Thus, additional nationwide as well as global large-scale database studies are expected, which will contribute to further improvements in clinical medicine.

**Acknowledgements**

The author appreciates all the Japanese institutes for sincere cooperation in nationwide database projects.

**Footnote**

*Conflicts of Interest:* The author has no conflicts of interest to declare.

**References**


